Recent Finacing
Recent Raise
Iroko Pharmaceuticals develops and commercializes lower-dose NSAID analgesics using SoluMatrix fine-particle technology, commercializing lead product ZORVOLEX (diclofenac) and maintaining an investigational NSAID pipeline.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor